Cancer Immunology, Immunotherapy

, Volume 58, Issue 9, pp 1481–1488

The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation

  • Mark Tuthill
  • Frederick Chen
  • Samantha Paston
  • Hugo De La Peña
  • Sylvie Rusakiewicz
  • Alejandro Madrigal
Focussed Research Review

DOI: 10.1007/s00262-009-0722-7

Cite this article as:
Tuthill, M., Chen, F., Paston, S. et al. Cancer Immunol Immunother (2009) 58: 1481. doi:10.1007/s00262-009-0722-7

Abstract

Allogeneic haematopoietic stem cell transplantation (HSCT) is an intensive medical treatment involving myeloablative chemo-radiotherapy followed by stem cell rescue using allogeneic haematopoietic stem cells harvested from HLA-matched donors, which is primarily used for the treatment of haematological malignancies. Cytomegalovirus (CMV) infection is one of the major causes of morbidity and death after HSCT. This focused research review highlights the advances made with research into CMV in the HSCT setting. It provides the reader with an overview of current CMV research into the prevention and management of CMV infection.

Keywords

CMVVaccineAdoptive cellular therapyArtificial antigen presenting cells

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Mark Tuthill
    • 1
  • Frederick Chen
    • 1
  • Samantha Paston
    • 1
  • Hugo De La Peña
    • 1
  • Sylvie Rusakiewicz
    • 1
  • Alejandro Madrigal
    • 1
  1. 1.The Anthony Nolan Research Institute, Royal Free HospitalLondonUK